The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
=== Thermotherapy === For pain management, heat can be used to relieve stiffness, and cold can relieve muscle spasms and pain. The use of ice or cold packs may be beneficial; however, further research is needed. A 2003 Cochrane review of seven studies between 1969 and 1999 found ice massage to be of significant benefit in improving range of motion and function, though not necessarily relief of pain. Cold packs could decrease swelling, but hot packs did not affect swelling. Heat therapy could increase circulation, thereby reducing pain and stiffness, but with the risk of inflammation and edema. Another review found no evidence of benefit from placing hot packs on joints.
=== Example case === The Appalachian CAD event of October 2002 illustrates some shortcomings of short-term weather models for predicting a CAD event. This event was characterized by a stable saturated layer of cold air from surface up to the 700mb pressure level over the states of Virginia, North Carolina, and South Carolina. This mass of cold air was blocked by the Appalachians and did not dissipate even as a coastal cyclone to east strengthened. During this event, short term weather models predicted this cold mass clearing, leading to fairer weather conditions for the region such as warmer conditions and the absence of a layer of stratus clouds. However, the model performed poorly because they did not account for excessive solar radiation transmission through the cloud layers and shallow mixing promoted by the model's convective parameterization scheme. While these errors have been corrected in updated models, they resulted in an inaccurate forecast.
==== Preventive trials ==== Failure of several drugs in Phase III clinical trials has led to AD prevention and early intervention for onset AD treatment endeavours. Passive anti-Aβ mAb treatment can be used for preventive attempts to modify AD progression before it causes extensive brain damage and symptoms. Trials using mAb treatment for patients positive for genetic risk factors, and elderly patients positive for indicators of AD are underway. This includes anti-AB treatment in Asymptomatic Alzheimer's Disease (A4), the Alzheimer's Prevention Initiative (API), and DIAN-TU. The A4 study on older individuals who are positive for indicators of AD but are negative for genetic risk factors will test Solanezumab in Phase III Clinical Trials, as a follow-up of previous Solanezumab studies. DIAN-TU, launched in December 2012, focuses on young patients positive for genetic mutations that are risks for AD. This study uses Solanezumab and Gautenerumab. Gautenerumab, the first fully human MAB that preferentially interacts with oligomerized Aβ plaques in the brain, caused significant reduction in Aβ concentration in Phase I clinical trials, preventing plaque formation and concentration without altering plasma concentration of the brain. Phase II and III clinical trials are currently being conducted.
Sources: en.wikipedia.org
== Risks or complications == The risks of flap surgery include infection, wound breakdown, fluid accumulation, bleeding, damage to nearby structures, and scarring. The most notable risk of this procedure is flap death, where the flap loses blood supply. This can be due to many reasons, but is commonly due to tension on the vascular supply and insufficient blood flow to the end segments of the flap. This can sometimes be fixed with another surgery or using additional methods of healing in the reconstructive ladder.
== Structural studies == As of late 2007, 8 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1VKN, PDB: 2CVO, PDB: 2G17, PDB: 2I3A, PDB: 2I3G, PDB: 2NQT, PDB: 2OZP, and PDB: 2Q49.
3D Realms was eventually acquired in part by Interceptor Entertainment, and in 2014, Interceptor announced plans to make a new Duke Nukem game, Duke Nukem: Mass Destruction. Gearbox filed suit against 3D Realms and Interceptor based on the fact that Gearbox now owned the rights to the Duke Nukem franchise. The case was settled out of court in August 2015, with 3D Realms and Interceptor acknowledging that Gearbox has full rights to the Duke Nukem series. Following the settlement, Gearbox released Duke Nukem 3D: 20th Anniversary Edition World Tour in September 2016. The game included new levels developed in conjunction with some of the original developers, re-recorded lines by original Duke voice actor Jon St. John, and new music from original composer Lee Jackson. It was released on October 11, 2016.
Sources: en.wikipedia.org
By 1830, the German mathematician Carl Friedrich Gauss had determined the boundary conditions governing capillary action (i.e., the conditions at the liquid-solid interface). In 1871, the British physicist Sir William Thomson (later Lord Kelvin) determined the effect of the meniscus on a liquid's vapor pressure—a relation known as the Kelvin equation. German physicist Franz Ernst Neumann (1798–1895) subsequently determined the interaction between two immiscible liquids. Albert Einstein's first paper, which was submitted to Annalen der Physik in 1900, was on capillarity.
In January 2023, Whirlpool and Arçelik A.Ş. agreed to start a new joint venture, Beko Europe B.V., which was to take over Whirlpool's appliance business in Europe, Middle East, and Africa. In August 2023, the Competition and Markets Authority started a merger inquiry, deciding in October 2023 that an in-depth investigation into this joint venture would be needed to ensure that it would not reduce competition in the UK market. This process concluded in March 2024, allowing the joint venture to go through. Arçelik owns 75% of Beko Europe while Whirlpool owns 25%, and the new joint venture now operates former Whirlpool brands such as Hotpoint and Indesit. In February 2024, Whirlpool announced the sale of a 24% stake in its Indian subsidiary for $428 million, retaining a 51% ownership. Supermicro will replace Whirlpool in the S&P 500 starting at market open March 18, 2024. It was possible after the sequential decline in Whirlpool's market cap, from 14.2B in the end of 2021 to less than 6B in March 2024. In 2024, Whirlpool finalized major aspects of its portfolio transformation to reshape itself into a higher-growth, higher-margin business focused primarily on the Americas. As part of this geographic consolidation, the company successfully reduced its ownership stake in Whirlpool of India from a majority position to a minority holding of approximately 40%. Throughout 2025, Whirlpool faced a challenging macroeconomic environment characterized by depressed U.S. housing market activity and weakened discretionary consumer demand due to home affordability issues.
Molecular: HCHO + hν → H2 + CO (λ < 360 nm) Radical: HCHO + hν → H + HCO (λ < 330 nm) The H and HCO radicals react with the atmospheric O2 to form hydroperoxyl (HO2) radicals, giving a net radical channel of:
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.